Background Deposition of tau aggregates is a pathological hallmark of Alzheimer's disease
that is closely linked both spatially and temporally to emergence of neurodegeneration and …

Well-authenticated biomarkers can provide critical insights into the biological basis of
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …

Several promising plasma biomarkers for Alzheimer's disease have been recently
developed, but their neuropathological correlates have not yet been fully determined. To …

As the leading cause of dementia, Alzheimer's disease (AD) is a major burden on affected
individuals, their families and caregivers, and healthcare systems. Although AD can be …

Studies have shown that women on the Alzheimer's disease (AD) continuum have more
pathological tau in the brain and cerebrospinal fluid (CSF), than men. Some studies have …

INTRODUCTION Plasma biomarkers are promising tools for Alzheimer's disease (AD)
diagnosis, but comparisons with more established biomarkers are needed. METHODS We …

Alzheimer's disease (AD) characterization has progressed from being indexed using clinical
symptomatology followed by neuropathological examination at autopsy to in vivo signatures …

Blood exosomes are emerging as potential biomarkers for diagnosing brain diseases such
as Alzheimer's disease (AD). There is currently a lack of an ultrasensitive technology for …

Alzheimer's disease (AD) is a long-term neurodegenerative disease that poses a serious
threat to human life and health. It is very important to develop a portable quantitative device …

Simple Summary Tau is an important protein for maintaining the shape and normal function
of nerve cells. There are many diseases that are identified by changes in this protein, yet …